Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.

Pathology oncology research : POR - 1 Jan 2016

Theurer Julie A, Stecho William, Yoo John, Kwan Keith, Wehrli Bret, Harry Vimla, Black Morgan, Pinto Nicole, Winquist Eric, Palma David, Richter Suzanne, Barrett John W, Danielle MacNeil S, Fung Kevin, Howlett Christopher J, Nichols Anthony C

Abstract excerpt

PIK3CA is the only frequently-mutated, directly druggable oncogene in head and neck squamous cell carcinoma (HNSCC). However, it is unclear if a molecularly-driven intervention trial can be launched successfully, particularly within a single-institution setting secondary to the infrastructure necessary for mutation detection, mutation prevalence, and patient willingness to participate. This study aimed to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Feasibility Studies

Share to Head and Neck Neoplasms

Share to Molecular Targeted Therapy

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Source

Identifiers

PMID: 26271341
DOI: 10.1007/s12253-015-9970-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.PMID 26271341Read ↗

High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer.Semantic proximity Read ↗

Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.Semantic proximity Read ↗

Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.Semantic proximity Read ↗

Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH TrialSemantic proximity Read ↗

<i>PIK3CA</i> Mutations in Head and Neck Squamous Cell CarcinomaSemantic proximity Read ↗

Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.Semantic proximity Read ↗

PIK3CA Hotspot Mutations in Saliva as a Diagnostic Marker in Oral Squamous Cell Carcinoma Patients.Semantic proximity Read ↗

Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.Semantic proximity Read ↗

Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma.Semantic proximity Read ↗

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.Semantic proximity Read ↗

Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.